LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Noguerado Asensio, Arturo"
  2. AU="Elías-Rodríguez, Pilar"
  3. AU="Yang, Qing-Yong"
  4. AU="Jonas, Wenke"
  5. AU="Khan, Nawal"
  6. AU="Martini, Lígia A"
  7. AU="Guzzetta, Melissa" AU="Guzzetta, Melissa"
  8. AU="Reiter, Gregor S"
  9. AU="Alberghina, Daniela"
  10. AU=D'Arena Giovanni AU=D'Arena Giovanni
  11. AU="Rutland, Catrin S"
  12. AU="Gocher-Demske, Angela M"
  13. AU="Koide, S S"
  14. AU=Barnbaum Deborah R AU=Barnbaum Deborah R
  15. AU=Xiang Hongfei AU=Xiang Hongfei
  16. AU="Whitehall, Julia"
  17. AU=Silva Severino Jefferson Ribeiro da
  18. AU="Piñero-Pérez, Rocío"
  19. AU="Voss, Stephan"
  20. AU="Jović, Ines"
  21. AU="Pérez-Guerrero, Edsaúl Emilio"
  22. AU="Akiyama, Shoko"
  23. AU="Greene, Wendy R"
  24. AU="Renzetti, Paolo"
  25. AU="Knöpfle, K T"
  26. AU="Peitzsch, Mirko" AU="Peitzsch, Mirko"
  27. AU=Bonet-Sola Daniel
  28. AU="Martín-Alfonso, J.E."
  29. AU=Ramesh BA
  30. AU="Dayanandan, Selvadurai"
  31. AU="Strathmann, Eike A"
  32. AU=Hewitt Stephen M
  33. AU="Meroni, Marco"
  34. AU="Gutierrez Amezcua, Jose Manuel"
  35. AU="Pfeifer, Susanne P"
  36. AU=McGrath Eric J
  37. AU="Wang, Pengyu"
  38. AU="Becker, Joscha Nico"
  39. AU="Chillrud, Steven N"
  40. AU=Werner L P
  41. AU="Tianmin Xu"
  42. AU="Matsagkas, Miltos"
  43. AU="Cosentino, Claudia"
  44. AU="Radbruch, Lukas"
  45. AU=Edwards Justin P.
  46. AU="Morse, Dan J"
  47. AU="Priya, Vansh"
  48. AU="Chen, Eric R"
  49. AU=Behrens Kevin G.
  50. AU=Radtke Heather B
  51. AU="Erdmann, Kati"
  52. AU="Anh, Nguyen P Q"
  53. AU="Arias, Manuel"
  54. AU="Badhrees, I."

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Nuevos fármacos antituberculosos en la tuberculosis resistente y multirresistente.

    Ramírez Lapausa, Marta / Pascual Pareja, José Francisco / Noguerado Asensio, Arturo

    Medicina clinica

    2013  Band 141, Heft 7, Seite(n) 306–313

    Abstract: Drug-resistant tuberculosis is a globally emerging problem with a rising incidence. According to the WHO in 2008, 17% of strains of Mycobacterium tuberculosis, in untreated cases were resistant to at least one drug and 3.6% were resistant to rifampicin ... ...

    Titelübersetzung New tuberculosis drugs in resistant and multiresistant tuberculosis.
    Abstract Drug-resistant tuberculosis is a globally emerging problem with a rising incidence. According to the WHO in 2008, 17% of strains of Mycobacterium tuberculosis, in untreated cases were resistant to at least one drug and 3.6% were resistant to rifampicin and isoniazid, which is called multidrug-resistant tuberculosis. The problem is greater in patients previously treated and in some countries, where rates of multidrug resistance reach 60%. Approximately 5% of multidrug-resistant tuberculosis patients are also resistant to any fluoroquinolone and at least one injectable drug, being called extensively drug-resistant tuberculosis. The treatment of these forms of tuberculosis requires the use of second-line drugs, which causes higher cost, higher toxicity and a longer duration of treatment. There is a need for new compounds with efficacy and safety profiles better than those currently used to treat these forms of tuberculosis. In the last decade different drugs have being reassessed and appeared, which are at different stages of development.
    Mesh-Begriff(e) Antitubercular Agents/classification ; Antitubercular Agents/economics ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Clinical Trials as Topic ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination ; Drugs, Investigational/classification ; Drugs, Investigational/economics ; Drugs, Investigational/pharmacology ; Drugs, Investigational/therapeutic use ; Extensively Drug-Resistant Tuberculosis/drug therapy ; Extensively Drug-Resistant Tuberculosis/epidemiology ; Humans ; Mycobacterium tuberculosis/drug effects ; Tuberculosis/drug therapy ; Tuberculosis/epidemiology ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/epidemiology
    Chemische Substanzen Antitubercular Agents ; Drugs, Investigational
    Sprache Spanisch
    Erscheinungsdatum 2013-10-05
    Erscheinungsland Spain
    Dokumenttyp English Abstract ; Journal Article ; Review
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2013.01.039
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.279: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014).

    Ramírez-Lapausa, Marta / Pascual Pareja, José Francisco / Carrillo Gómez, Raquel / Martínez-Prieto, Mónica / González-Ruano Pérez, Patricia / Noguerado Asensio, Arturo

    Enfermedades infecciosas y microbiologia clinica

    2016  Band 34, Heft 2, Seite(n) 85–90

    Abstract: Introduction: Although linezolid is known to be effective when used as an adjunct therapy in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB), the clinical experience is limited. In this study the efficacy and adverse effects of ... ...

    Abstract Introduction: Although linezolid is known to be effective when used as an adjunct therapy in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB), the clinical experience is limited. In this study the efficacy and adverse effects of linezolid treatment were evaluated.
    Methods: A retrospective study of tolerability and efficacy of linezolid in MDR-TB patients was performed in Madrid, Spain. Demographic characteristics, microbiological and clinical features and data on treatment tolerability were collected. Regimens were constructed with a target of prescribing, at least, five anti-tuberculosis agents likely to be effective. Linezolid, at a dosage of 1200 or 600 mg daily, was included to complete the treatment if no other sensitive drugs were available. Vitamin B6 was used to reduce toxicity. Treatment outcome and clinical status at last contact were compared between patients with linezolid-containing regimens and with those without linezolid-containing regimens.
    Results: During the period 1998-2014, 55 patients with MDR-TB received treatment. In 21 of these patients, linezolid was added. The median of linezolid administration was 23.9 months (IQT 13.1-24.7). Patients using linezolid showed a greater resistance to drugs, with a median of 6 (IQR 5-7) compared with those who did not use it, with a median of 4 drugs (IQR 3-5) (p<0.001). The median time to sputum culture conversion of the patients in the linezolid group (73.5 days) did not differ significantly from those in the non-linezolid group (61 days) (p=0.29). There were no significant differences in the outcomes of the two patient groups. There were no reported adverse events in 81% of patients assigned to linezolid therapy. Only four patients developed toxicity attributed to linezolid. The most serious adverse event in these patients was anemia observed in the two patients treated with 1200 mg per day. One of them also developed moderate paresthesia. In both cases the dosage was reduced to 600 mg per day, with improvement of the anemia and paresthesias. No patients stopped linezolid therapy.
    Conclusion: A daily dosage of 600 mg of linezolid was well tolerated without stopping treatment in any case. The efficacy of the treatment and the outcomes were similar in both the linezolid and non-linezolid group.
    Mesh-Begriff(e) Adult ; Antitubercular Agents/therapeutic use ; Female ; Humans ; Linezolid/therapeutic use ; Male ; Retrospective Studies ; Spain ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy
    Chemische Substanzen Antitubercular Agents ; Linezolid (ISQ9I6J12J)
    Sprache Englisch
    Erscheinungsdatum 2016-02
    Erscheinungsland Spain
    Dokumenttyp Journal Article
    ZDB-ID 1070941-1
    ISSN 1578-1852 ; 0213-005X
    ISSN (online) 1578-1852
    ISSN 0213-005X
    DOI 10.1016/j.eimc.2015.04.003
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3204: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Evolución y tratamiento de pacientes con tuberculosis multirresistente.

    Ramírez Lapausa, Marta / Pascual Pareja, José Francisco / Amer López, Mariam / Amer Pérez, Mariam / Vidal Pérez, José Luis / Noguerado Asensio, Arturo

    Medicina clinica

    2012  Band 138, Heft 15, Seite(n) 643–649

    Abstract: Background and objective: Although progress has been made to reduce the global incidence of tuberculosis, the emergence of multidrug-resistant tuberculosis during the past decade threatens to limit these results. The aim of this study is to evaluate the ...

    Titelübersetzung Outcome and treatment among patients with multidrug-resistant tuberculosis.
    Abstract Background and objective: Although progress has been made to reduce the global incidence of tuberculosis, the emergence of multidrug-resistant tuberculosis during the past decade threatens to limit these results. The aim of this study is to evaluate the geographic distribution, clinical and microbiological characteristics and outcomes of multidrug-resistant tuberculosis patients in Spain.
    Patients and methods: Retrospective study between January 1998 and December 2010 of patients attended in Cantoblanco-La Paz Hospital Isolation Internal Medicine Unit.
    Results: Forty-seven patients were studied, with a mean age of 36 years. There were 33 male. Sixty-four per cent were immigrants and the mean residence time in Spain was 12 months. Twenty-six patients (55.3%) were new cases. Patients were resistant to a median of 5 drugs (interquartile range [IQR] 3-7) and 3 patients had extensively drug-resistant tuberculosis. Cultures became negative after a median of 68.5 days (IQR 49.5-91.8). The median length of hospitalization was 2.75 months (IQR 1.3-4.6). They were treated during a median of 22.4 months (IQR 15.3-24.3). The overall success rate was 93%. A directly observed treatment was carried out in 79% of patients. Sixty-eight per cent patients presented side effects. In 75% of the cases the effects were mild and moderate with no need to replace the drug. Fourteen patients were followed up for a median of 40.5 months (IQR 7.4-55) and no clinical or bacteriological manifestation of disease was detected.
    Conclusions: Most patients with multidrug-resistant tuberculosis can be cured with the use of appropriate and intensive regimens, management of side effects and implementation of strategies to improve adherence to treatment.
    Mesh-Begriff(e) Adult ; Antitubercular Agents/adverse effects ; Antitubercular Agents/therapeutic use ; Directly Observed Therapy/utilization ; Emigrants and Immigrants/statistics & numerical data ; Extensively Drug-Resistant Tuberculosis/drug therapy ; Extensively Drug-Resistant Tuberculosis/epidemiology ; Extensively Drug-Resistant Tuberculosis/ethnology ; Extensively Drug-Resistant Tuberculosis/microbiology ; Female ; Humans ; Length of Stay ; Male ; Retrospective Studies ; Spain/epidemiology ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/epidemiology ; Tuberculosis, Multidrug-Resistant/ethnology ; Tuberculosis, Multidrug-Resistant/microbiology
    Chemische Substanzen Antitubercular Agents
    Sprache Spanisch
    Erscheinungsdatum 2012-05-26
    Erscheinungsland Spain
    Dokumenttyp English Abstract ; Journal Article
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2011.10.029
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.279: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang